CD47 and cancer: In HMPB/BLZ945/anti-SIRPα@ATRA@fibrin treatment, HMPB exerts CAT-like function, anti-SIRPα antibodies and BLZ945 promote macrophage polarization from M2- to M1-like phenotype by blocking the corresponding CD47-SIRPα and CSF-1/CSF-1R signal axes combined with ATRA-induced differentiation of cancer stem cells, which restores the phagocytosis and killing ability of macrophages to tumor cells, effectively inhibiting postoperative recurrence of hepatocellular carcinoma (HCC).